Overview

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.